NGeneBio participated in the Korean Society of Clinical Laboratory Science Spring Symposium, held at BEXCO in Busan from April 27 to April 28.

During this event, NGeneBio showcased its NGS precision diagnostic technology and introduced new products to a diverse audience, including hospital staff, university representatives, research institutions, and public sector professionals. They particularly highlighted their blood cancer precision diagnostic product, HEMEaccuTest™, which aligns with the topics presented by international speakers. Additionally, they introduced a forthcoming FLT3-ITD test product for minimal residual disease in acute myeloid leukemia (AML). This product offers high sensitivity and accuracy in detecting FLT3 gene ITD of previously unmeasurable lengths, and it can simultaneously identify mutations in the Tyrosine Kinase Domain (TKD), generating significant interest in the industry.

NGeneBio is committed to expanding the market by providing innovative products through collaboration and active information exchange with healthcare professionals and companies, both domestically and internationally.